Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011612 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Kenneth Johnson und 16 weiteren Autor:innen. Beteiligte Einrichtung: Visterra, Inc., Waltham, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Immunoconjugates, Bacterial Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CARB-X, Visterra Inc.
Abstract (Originalsprache)
The increase in emerging drug resistant Gram-negative bacterial infections is a global concern. In addition, there is growing recognition that compromising the microbiota through the use of broad-spectrum antibiotics can impact long term patient outcomes. Therefore, there is the need to develop new bactericidal strategies to combat Gram-negative infections that would address these specific issues. In this study, we report and characterize one such approach, an antibody-drug conjugate (ADC) that combines (i) targeting the surface of a specific pathogenic organism through a monoclonal antibody with (ii) the high killing activity of an antimicrobial peptide. We focused on a major pathogenic Gram-negative bacterium associated with antibacterial resistance: Pseudomonas aeruginosa . To target this organism, we designed an ADC by fusing an antimicrobial peptide to the C-terminal end of the V H and/or V L -chain of a monoclonal antibody, VSX, that targets the core of P . aeruginosa lipopolysaccharide. This ADC demonstrates appropriately minimal levels of toxicity against mammalian cells, rapidly kills P . aeruginosa strains, and protects mice from P . aeruginosa lung infection when administered therapeutically. Furthermore, we found that the ADC was synergistic with several classes of antibiotics. This approach described in this study might result in a broadly useful strategy for targeting specific pathogenic microorganisms without further augmenting antibiotic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Visterra, Inc., Waltham, Massachusetts, United States of America.
- Inserm UMR-S 1250 P3 Cell, Université de Reims-Champagne-Ardenne, Reims, France.
- CNRS, INSERM, Institut Necker Enfants Malades-INEM, F-75015 Paris, France; Faculté de Médecine, University of Paris City, Paris, France.
- Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
- Department of Clinical Microbiology, Fédération Hospitalo-Universitaire Prématurité (FHU PREMA), Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris City, Paris, France.
- Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
ORCID-Profile: David Skurnik
Förderung
- CARB-X
- Visterra Inc
Zitieren
APA
Johnson, K., Delaney, J. C., Guillard, T., Reffuveille, F., Varin-Simon, J., Li, K., Wollacott, A., Frapy, E., Mong, S., Tissire, H., Viswanathan, K., Touti, F., Babcock, G. J., Shriver, Z., Pentelute, B. L., Plante, O., & Skurnik, D. (2023). Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011612
Vancouver
Johnson K, Delaney JC, Guillard T, Reffuveille F, Varin-Simon J, Li K, et al. Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011612
BibTeX
@article{Johnson2023,
author = {Johnson, Kenneth and Delaney, James C and Guillard, Thomas and Reffuveille, Fany and Varin-Simon, Jennifer and Li, Kai and Wollacott, Andrew and Frapy, Eric and Mong, Surin and Tissire, Hamid and Viswanathan, Karthik and Touti, Faycal and Babcock, Gregory J and Shriver, Zachary and Pentelute, Bradley L and Plante, Obadiah and Skurnik, David},
title = {Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011612}
}
EUVIMED